HomeBUSINESS
BUSINESS

Tagrisso Selected for 23.7% of Japanese NSCLC Patients Whose Cancer Progressed on EGFR-TKIs: Observational Study
(Apr.17.2018)

A multicenter prospective observational study found that Tagrisso (osimertinib) was administered to 23.7% of Japanese patients with T790M mutation-positive non-small cell lung cancer (NSCLC) whose cancer progressed during treatment with EGFR-tyrosine kinase inhibitors (TKIs), the Japan arm of AstraZeneca plc announced on April 16 ...
(LOG IN FOR FULL STORY)

News Calendar